Revolution Medicines, Inc. RVMD Accretion (Amortization) of Discounts and Premiums, Investments
Accretion (Amortization) of Discounts and Premiums, Investments at other companies
Other financials
Where this comes from
Reported directly by Revolution Medicines, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.
The official record: Revolution Medicines, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Revolution Medicines, Inc.'s accretion (amortization) of discounts and premiums, investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Revolution Medicines, Inc.'s accretion (amortization) of discounts and premiums, investments?
- Revolution Medicines, Inc. (RVMD) reported accretion (amortization) of discounts and premiums, investments of $3.22M in Q1 2026.
- How has Revolution Medicines, Inc.'s accretion (amortization) of discounts and premiums, investments changed year-over-year?
- Revolution Medicines, Inc.'s accretion (amortization) of discounts and premiums, investments decreased by 67.2% year-over-year, from $9.82M to $3.22M.
- What is the long-term trend for Revolution Medicines, Inc.'s accretion (amortization) of discounts and premiums, investments?
- Over 4 years (2021 to 2025), Revolution Medicines, Inc.'s accretion (amortization) of discounts and premiums, investments has grown at a 74.3% compound annual growth rate (CAGR), from -$3.01M to $27.83M.